Posted by Michael Wonder on 01 Feb 2024
Biosyngen announces FDA fast track designation for BST02 in treatment of liver cancer
1 February 2024 - Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted fast track designation by the US FDA for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
BST02 has received approval from the FDA for Phase I/II clinical trial in October 2023 and has also been approved by the Center for Drug Evaluation of the China National Drug Administration in January 2024.
